Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Breast Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
48 drugs · 217 active trials
17 drugs · 330 active trials
43 drugs · 1,254 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 14 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Daratumumab | Phase 1 | Phase 1 | 1 | 1 | 0 | 2 | 0 | — | — | Mar 27, 2018 |
| FOLFOX Regimen | Phase 1 | Phase 1 | 1 | 1 | 0 | 2 | 0 | — | — | Nov 15, 2013 |
| Berzosertib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 24, 2020 |
| Elimusertib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 25, 2021 |
| Lenalidomide | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 30, 2026 |
| Pidnarulex | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 5, 2026 |
| Belinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | Mar 27, 2018 |
| Onalespib | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | Nov 19, 2010 |
| Samotolisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | Jul 31, 2012 |
| Abiraterone | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Apr 1, 2020 |
| Birabresib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Oct 23, 2014 |
| Dinaciclib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 21, 2012 |
| Sonidegib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-07 |
| 2-Deoxy-D-glucose | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-02 |
| Abexinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 31, 2021 |
| Alitretinoin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 1996-05 |
| Aurora A Kinase Inhibitor LY3295668 Erbumine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 2, 2019 |
| Axitinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 11, 2023 |
| Brentuximab Vedotin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 29, 2020 |
| Carfilzomib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 27, 2018 |
| Dacarbazine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 14, 2007 |
| Enasidenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| FOLFIRI Regimen | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-12 |
| HER2 Inhibitor CP-724,714 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2003-01 |
| Idelalisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Infigratinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 13, 2020 |
| Lorlatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Lumretuzumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 6, 2013 |
| PI3Kbeta Inhibitor AZD8186 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 24, 2018 |
| Picoplatin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-04 |
| Porcupine Inhibitor WNT974 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2011 |
| Rebastinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-07 |
| Rituximab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 27, 2018 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.